Skip to main content

Table 1 Demographics and clinical characteristics

From: A feasibility study exploring the role of pre-operative assessment when examining the mechanism of ‘chemo-brain’ in breast cancer patients

 

Chemotherapy n = 8

No chemotherapy n = 6

Age (years)

 Mean (SD)

52.6 (3.9)

50.2 (2.3)

 Range

50–61

47–53

Partner

 Yes

4

5

Education

 Higher

3

4

 Further

2

1

 Secondary

3

1

FSIQa

 Mean (SD)*

111.1 (7.4)

120.8 (4.5)

 Range

106–123

112–124

Employed

 Full-time

5

4

 Part-time

3

2

Cancer stage*,b

 I

0

4

 II

1

1

 III

7

0

Type of surgery

 Mastectomy

2

1

 WLE

6

5

Node sampling

 Yes

8

6

Chemotherapy regimen

 AC

1

 FEC 75

2

 FEC-Tc

5

Herceptin

 Yes

2

Radiotherapy

 Yes

7

5

Endocrine therapy by T3

 Yes

3

6

Postmenopausal at baseline

 Yes

3

2

Prior HRT

 Yes

2

1

Baseline Hb level (g/L)

 Mean (SD)

135.4 (10.9)

133.8 (7.6)

 Range

120–151

126–145

  1. AC doxorubicin and cyclophosphamide, BMI body mass index, FEC 75 fluorouracil, epirubicin (75 mg/m2) and cyclophosphamide, FEC-T fluorouracil, epirubicin, cyclophosphamide and docetaxel, FSIQ full scale intelligence quotient, G-CSF granulocyte-colony stimulating factor, Hb haemogloblin, HRT hormone replacement therapy, SD standard deviation, WLE wide local excision
  2. p < 0.05
  3. aDerived from the National Adult Reading Test
  4. bOne participant had an ungraded tumour due to unusual presentation
  5. cOne woman had neo-adjuvant FEC-T chemotherapy